$GH

Hidalgo Medina Manuel sold $130K of GH

Hidalgo Medina Manuel sold 1,000 shares of Guardant Health, Inc. (GH) at $130.06 ($0.13M total) on 2026-05-28.

Original reporting
SEC EDGAR · Hidalgo Medina Manuel
Published May 29, 2026, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The disclosure updates insider-trading visibility but does not provide new company performance, guidance, or deal information.

02

Market read

Traders may monitor GH for any follow-on insider activity, but the filing alone is unlikely to drive a major repricing.

03

What to watch

No 10b5-1 plan is cited; traders may want to check prior Form 4 cadence and whether sales cluster around specific events or option exercises.

Relevance 6/10Novelty 6/10Timing: Filed after-hours/late day (2026-05-29T17:30:38-04:00) following the 2026-05-28 sale.

Background

The article is an SEC Form 4 disclosure reporting an insider (director) transaction in Guardant Health shares.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health director Hidalgo Medina Manuel filed a Form 4 open-market sale of 1,000 shares at ~$130.06 on 2026-05-28.

Expected impact

Low near-term impact; any reaction is likely limited unless part of a broader selling pattern.

Evidence & confidence

The filing is a director open-market sale with no 10b5-1 plan stated and no accompanying company-specific operational news.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

A single director open-market sale may reflect diversification or routine liquidity needs rather than negative fundamentals.

Key entities

  • Guardant Health, Inc.

    Publicly traded company whose director filed the Form 4 insider sale.

  • Hidalgo Medina Manuel

    Director who sold 1,000 GH shares at ~$130.06/share.

Related articles

$GHHighAI 9/10

Guardant Health (GH) Q2 2026 Earnings Call Transcript

Guardant Health (GH) reported Q2 2026 revenue of $335 million, up 44% year over year, driven by Oncology, Biopharma & Data, and Screening. Oncology revenue was $219.1 million, up 38%, with test volumes around 104,000. Full-year guidance: revenue $1.34 to $1.36 billion and free cash flow burn $195 to $205 million.

$GHMedAI 8/10

New blood test to detect colon cancer clears FDA approval

The FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in adults aged 45+ at average risk. In a study of 48,000+ people, it detected about 80% of colorectal cancers and correctly tested negative in about 90% without cancer or advanced precancer. It is expected to launch this fall with Abbott. Guardant Health’s Shield was approved in 2024.

$GHMedAI 8/10

Guardant Health, Inc. Q2 2026 Earnings Call Summary

Guardant Health reported 44% YoY Q2 2026 revenue growth, citing strong Oncology and Screening performance. It raised full-year 2026 revenue guidance to $1.34B-$1.36B and expects lower Shield cost per test. FDA approval of Guardant360 Liquid CDx and UnitedHealth coverage for Shield from Aug. 1, 2026 are key catalysts.

$GHHighAI 9/10

Why is Guardant Health stock surging today?

Nasdaq sees best day in over a month as Microsoft breathes life back into AI trade Investing.com -- Guardant Health stock surged 8.8% in after-hours trading after the Palo Alto-based liquid biopsy pioneer reported second-quarter 2026 results that significantly exceeded revenue expectations, with sales reaching $335 million — a 44% year-over-year increase that beat the Wall Street consensus of roughly $314 million by approximately 6.4%.